Antiparkinsonian COMT Inhibitors

Antiparkinsonian catechol-O-methyltransferase (COMT) inhibitors are a therapeutic class of medications used exclusively as adjunctive therapy alongside levodopa and a dopa decarboxylase inhibitor in patients with Parkinson’s disease They function by selectively inhibiting the COMT enzyme, which prevents the peripheral degradation of levodopa into 3-O-methyldopa

Antiparkinsonian catechol-O-methyltransferase (COMT) inhibitors are a therapeutic class of medications used exclusively as adjunctive therapy alongside levodopa and a dopa decarboxylase inhibitor in patients with Parkinson’s disease Consequently, these agents are primarily indicated to reduce motor fluctuations, such as end-of-dose "wearing-off" and "off" episodes, in fluctuating Parkinson's disease

They function by selectively inhibiting the COMT enzyme, which prevents the peripheral degradation of levodopa into 3-O-methyldopa This mechanism prolongs the plasma half-life of levodopa, increases its transport across the blood-brain barrier into the central nervous system, and provides more continuous dopaminergic stimulation

This mechanism prolongs the plasma half-life of levodopa, increases its transport across the blood-brain barrier into the central nervous system, and provides more continuous dopaminergic stimulation

Consequently, these agents are primarily indicated to reduce motor fluctuations, such as end-of-dose "wearing-off" and "off" episodes, in fluctuating Parkinson's disease

Consequently, these agents are primarily indicated to reduce motor fluctuations, such as end-of-dose "wearing-off" and "off" episodes, in fluctuating Parkinson's disease